Fig. 2. Linear predictor for the fit of the Log₂-based DF₅₀.

The Log₂DF₅₀ was modelled with a longitudinal random intercept nested Linear Mixed Model, against time, treatment and the interaction of time and treatment, taking into account 2 (baseline and 6 months) or 3 (baseline, 6 and 12 months) timepoints, nesting 15 antigens per patient, and 30 patients in each of 7 treatment subgroups. Nested models keep the connection between the patient and the antigens. a At 6 months, and (b) At 12 months after the start of treatment. Log₂ Binary logarithm, DF₅₀ Dilution Factor 50 at which 50% of the original reactivity remains, BZN Benznidazole.